Pharmaceuticals

What Key Growth Drivers Are Shaping The Quadrivalent Market Forecast Toward $13.91 Billion?

September 23, 2025 by Marketing Posting

Claim 30% Off Global Market Reports With Code ONLINE30 – Insights on Tariff Effects, Global Trade, and Industry Disruptors

#How Is The Quadrivalent Market Expected To Grow In Terms Of Size?#_x000D_

The market for quadrivalent has seen a robust expansion in the past years. This market is projected to escalate from $8.87 billion in 2024 to $9.51 billion in 2025, with a compound annual growth rate (CAGR) of 7.2%. The historical period’s growth can be credited to factors such as disease complexity, educational campaigns, previous health incidents, expansion in healthcare, and technological advancements._x000D_

_x000D_

The market size for quadrivalent is anticipated to witness substantial expansion in the coming years, reaching “$13.91 billion by the year 2029 with a 10.0% compound annual growth rate (CAGR). The projected growth during this period is a result of various factors including global health occurrences, competitive influences, educational drives, regulatory shifts, and changing disease trends. Key trends to watch out for during this forecast period are disease prevalence, regulatory alterations, healthcare infrastructure, customer awareness, education, and the competitive scenario._x000D_

_x000D_

#Get A Free Sample Of The Report:#_x000D_

https://www.thebusinessresearchcompany.com/sample.aspx?id=9335&type=smp_x000D_

_x000D_

#What Drivers Are Accelerating Expansion Of The Quadrivalent Market?#_x000D_

The growth of the quadrivalent market is predicted to be driven by the increasing occurrence of chronic and infectious diseases. Chronic diseases are persistent illnesses that stem from genetics and lifestyle, while infectious diseases are any disorders triggered by an infectious agent such as a virus, bacteria, fungus, or protozoan. Quadrivalent vaccines play a vital role in curbing severe infections and decreasing morbidity and mortality from diseases other than the specific ones they are created to combat. These vaccines are utilized to ward off chronic (non-communicable) diseases when infectious agents are instrumental in causing cancer. For instance, a report from the Centers for Disease Control and Prevention, a non-profit organization based in the US, stated that in Week 37 of September 2024, 0.5% of specimens tested positive for influenza, with 91.4% being influenza A and 8.6% influenza B. Meanwhile, cumulatively from October 1, 2023 (Week 40), 8.7% of specimens tested positive, dominated by 69.2% influenza A and 30.8% influenza B. This suggests a higher cumulative positivity rate and a greater frequency of influenza B cases. Consequently, the growing incidence of chronic and infectious diseases is stimulating the quadrivalent market’s expansion._x000D_

_x000D_

#Which Segments Define The Structure Of The Quadrivalent Market?#_x000D_

The quadrivalent market covered in this report is segmented – _x000D_

_x000D_

1) By Type: Intradermal Shot, Intramuscular Injection, Nasal Spray_x000D_

2) By Technology: Conjugated, Live, Inactivated, Recombinant, Toxoid, Other Technologies_x000D_

3) By Disease: Cancer, Hepatitis, Pneumococcal Disease, COVID-19, Influenza, Human Papilloma Virus, Meningococcal Disease, Polio, Rotavirus, Other Diseases_x000D_

4) By Age Group: Pediatric, Adult_x000D_

5) By Distribution Channel: Hospital And Pharmacy, Government Suppliers, Other Channels (NGOs)_x000D_

_x000D_

Subsegments:_x000D_

1) By Intradermal Shot: Standard Intradermal Injection, Needle-Free Intradermal Delivery _x000D_

2) By Intramuscular Injection: Standard Intramuscular Injection, Adjuvanted Intramuscular Injection _x000D_

3) By Nasal Spray: Live Attenuated Nasal Spray, Inactivated Nasal Spray_x000D_

_x000D_

#What Strategic Shifts And Innovations Are Influencing The Quadrivalent Market?#_x000D_

The surge of product innovations represents an emerging trend within the quadrivalent market. The principal firms in this sector are concentrating their efforts on creating novel solutions to cement their standing. For example, AstraZeneca, a pharmaceutical corporation based in the UK, introduced FluMist quadrivalent (Influenza Vaccination Live, Intranasal) in September 2022. This FDA-approved nasal-spray flu vaccine, suitable for individuals aged between 2 and 49, can be given without a needle. The live attenuated influenza vaccine (LAIV), which comes in either trivalent or quadrivalent versions, is included in most health insurance plans and also in the vaccines for children’s program._x000D_

_x000D_

#Who Are The Most Influential Companies In The Quadrivalent Market?#_x000D_

Major companies operating in the quadrivalent market include AstraZeneca Plc, Serum Institute of India Private Limited, Sanofi S.A., GlaxoSmithKline Plc, CSL Limited, Bharat Biotech International Limited, Hualan Biological Engineering Inc., Merck & Co. Inc., Johnson & Johnson Services Inc., Pfizer Inc., Bio Med Pvt. Ltd., Walvax Biotechnology Co. Ltd., Chongqing Zhifei Biological Products Co. Ltd., Emergent BioSolutions Inc., Biological E. Limited, GSK Biologicals SA, Institute of Vaccines and Biological Products Chinese Academy of Medical Sciences, Wuhan Institute of Biological Products Co. Ltd., Beijing Tian Tan Biological Products Co. Ltd., Shanghai Zhijiang Bio-pharm Co. Ltd., Bio Farma, Butantan Institute, Pasteur Institute of India, China National Biotec Group Co. Ltd. (CNBG) _x000D_

_x000D_

#Access The Complete Report Here:#_x000D_

https://www.thebusinessresearchcompany.com/report/quadrivalent-global-market-report_x000D_

_x000D_

#Which Region Is Forecasted To Lead The Quadrivalent Market In The Coming Years?#_x000D_

North America was the largest region in the quadrivalent market in 2024. The regions covered in the quadrivalent market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa_x000D_

_x000D_

#Customize Your Report Here:#_x000D_

https://www.thebusinessresearchcompany.com/customise?id=9335&type=smp_x000D_

_x000D_

#About The Business Research Company:#_x000D_

_x000D_

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game._x000D_

_x000D_

#Get in touch with us:#_x000D_

_x000D_

The Business Research Company: https://www.thebusinessresearchcompany.com/_x000D_

Americas +1 310-496-7795_x000D_

Asia +44 7882 955267 & +91 8897263534_x000D_

Europe +44 7882 955267_x000D_

Email us at info@tbrc.info_x000D_

_x000D_

#Follow us on:#_x000D_

_x000D_

LinkedIn: https://in.linkedin.com/company/the-business-research-company_x000D_